Expert Q&A
Expert Q&A
02/05/2026
Brian A. Bergmark, MD
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
02/05/2026